首页> 美国卫生研究院文献>Springer Open Choice >Phase I Clinical Study of ZYAN1 A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety Tolerability and Pharmacokinetics Following Oral Administration in Healthy Volunteers

【2h】

Phase I Clinical Study of ZYAN1 A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety Tolerability and Pharmacokinetics Following Oral Administration in Healthy Volunteers

机译：新型脯氨酰羟化酶（PHD）抑制剂ZYAN1的一期临床研究旨在评估健康志愿者口服后的安全性耐受性和药代动力学

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectiveThis phase I study of ZYAN1 was conducted to evaluate the safety, tolerability, and pharmacokinetics following oral administration in healthy volunteers.

机译：目的进行ZYAN1的I期研究以评估健康志愿者口服后的安全性，耐受性和药代动力学。

著录项

期刊名称 Springer Open Choice
作者
Kevinkumar A. Kansagra; Deven Parmar; Rajendra H. Jani; Nuggehally R. Srinivas; Jason Lickliter; Harilal V. Patel; Devang P. Parikh; Heather Heading; Hardik B. Patel; Rahul J. Gupta; Chintan Y. Shah; Maulik R. Patel; Vyom N. Dholakia; Raghav Sukhadiya; Mukul R. Jain; Krupi V. Parmar; Kinjal Barot;
展开▼
作者单位

展开▼
年(卷),期 -1(57),1
年度 -1
页码 87–102
总页数 16
原文格式 PDF
正文语种
中图分类外科学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers [J] . Kansagra Kevinkumar A., Parmar Deven, Jani Rajendra H., Clinical pharmacokinetics . 2018 ,第1期

机译：Zyan1，一种新型脯氨酰 - 羟化酶（PHD）抑制剂的临床研究，以评估在健康志愿者口服施用后的安全性，耐受性和药代动力学
2. Two Phase 1, Open‐Label, Single‐Dose, Randomized, Crossover Studies to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered Granules of Secnidazole (2 g) in Healthy Female Volunteers Under Different Administration Conditions [J] . Pentikis Helen S., Adetoro Nikki Clinical pharmacology in drug development . 2018 ,第5期

机译：两阶段1，开放标签，单剂量，随机交叉研究，以评估在不同给药条件下健康女性志愿者中口服施用的药代动力学，安全性和口服颗粒的药代动力学，安全性和耐受性
3. Pharmacokinetics, tolerability, and safety of the single oral administration of AGSAV301 vs Exforge: A randomized crossover study of healthy male volunteers [J] . ChoiH.Y., KimY.H., KimM.J., American journal of cardiovascular drugs: drugs, devices, and other interventions . 2014 ,第1期

机译：AGSAV301与Exforge单次口服给药的药代动力学，耐受性和安全性：健康男性志愿者的随机交叉研究
4. Pharmacokinetics and Tolerability of Sublingual Fentanyl in Healthy Japanese and Caucasian Volunteers: Phase I, Open-Label Single-Dose Study [C] . U. Lorch, F. Farrell, J. Kilborn, International Pain Clinic Congress . 2008

机译：健康日本和白种人志愿者舌下芬太尼的药代动力学和耐受性：I期，开放标签单剂量研究
5. Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-Clinical Mechanistic Assessment [D] . Moorthy, Ganesh P. 2015

机译：BEZ235，PI3K / mTOR抑制剂和依维莫司，mTOR抑制剂的新型组合的临床药代动力学：I期临床研究和非临床机制评估
6. Two Phase 1 Open‐Label Single‐Dose Randomized Crossover Studies to Assess the Pharmacokinetics Safety and Tolerability of Orally Administered Granules of Secnidazole (2 g) in Healthy Female Volunteers Under Different Administration Conditions [O] . Helen S. Pentikis, Nikki Adetoro -1

机译：两个阶段1开放标签单剂量随机交叉研究以评估在不同给药条件下健康女性志愿者中口服塞尼达唑颗粒（2 g）的药代动力学安全性和耐受性
7. Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers [O] . Kevinkumar A. Kansagra, Deven Parmar, Rajendra H. Jani, 2017

机译：Zyan1，一种新型脯氨酰 - 羟化酶（PHD）抑制剂的临床研究，以评估在健康志愿者口服施用后的安全性，耐受性和药代动力学

Phase I Clinical Study of ZYAN1 A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety Tolerability and Pharmacokinetics Following Oral Administration in Healthy Volunteers

摘要

著录项

相似文献

相关主题

期刊订阅